OBLN
Income statement / Annual
Last year (2024), Obalon Therapeutics, Inc.'s total revenue was $8.01 M,
an increase of 404.16% from the previous year.
In 2024, Obalon Therapeutics, Inc.'s net income was -$7.13 M.
See Obalon Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2024 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$8.01 M |
$1.59 M |
$3.28 M |
$9.10 M |
$9.91 M |
$3.39 M |
$4.04 M |
$3.54 M |
| Cost of Revenue |
$2.95 M
|
$1.00 M
|
$2.95 M
|
$5.42 M
|
$4.83 M
|
$2.81 M
|
$2.50 M
|
$2.91 M
|
| Gross Profit |
$5.06 M
|
$584.00 K
|
$331.00 K
|
$3.68 M
|
$5.09 M
|
$584.00 K
|
$1.54 M
|
$627.00 K
|
| Gross Profit Ratio |
0.63
|
0.37
|
0.1
|
0.4
|
0.51
|
0.17
|
0.38
|
0.18
|
| Research and Development Expenses |
$1.80 M
|
$2.45 M
|
$6.89 M
|
$10.70 M
|
$10.65 M
|
$9.87 M
|
$12.98 M
|
$5.77 M
|
| General & Administrative Expenses |
$6.93 M
|
$8.78 M
|
$16.67 M
|
$29.95 M
|
$28.83 M
|
$10.22 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$2.99 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$9.92 M
|
$8.78 M
|
$16.67 M
|
$29.95 M
|
$28.83 M
|
$10.22 M
|
$0.00
|
$0.00
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.49 M
|
$4.70 M
|
| Operating Expenses |
$11.73 M
|
$11.23 M
|
$23.56 M
|
$40.64 M
|
$39.48 M
|
$20.09 M
|
$16.47 M
|
$10.47 M
|
| Cost And Expenses |
$14.67 M
|
$12.23 M
|
$26.51 M
|
$46.07 M
|
$44.31 M
|
$22.90 M
|
$18.97 M
|
$13.38 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$843.00 K
|
$894.00 K
|
$581.00 K
|
$330.00 K
|
$192.00 K
|
$167.00 K
|
$166.00 K
|
| EBITDA |
-$6.67 M |
-$11.49 M |
-$22.78 M |
-$36.80 M |
-$34.44 M |
-$20.28 M |
-$15.39 M |
-$9.72 M |
| EBITDA Ratio |
-0.83
|
-7.24
|
-6.94
|
-4.04
|
-3.47
|
-5.98
|
-3.81
|
-2.75
|
| Operating Income Ratio |
-0.83
|
-6.7
|
-7.08
|
-4.06
|
-3.47
|
-5.75
|
-3.7
|
-2.78
|
| Total Other Income/Expenses Net |
-$423.00 K
|
-$1.69 M
|
-$446.00 K
|
-$415.00 K
|
-$374.00 K
|
-$962.00 K
|
-$624.00 K
|
-$50.00 K
|
| Income Before Tax |
-$7.09 M
|
-$12.33 M
|
-$23.68 M
|
-$37.38 M
|
-$34.77 M
|
-$20.47 M
|
-$15.56 M
|
-$9.89 M
|
| Income Before Tax Ratio |
-0.89
|
-7.77
|
-7.22
|
-4.11
|
-3.51
|
-6.03
|
-3.85
|
-2.79
|
| Income Tax Expense |
$39.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$50.00 K
|
| Net Income |
-$7.13 M
|
-$12.33 M
|
-$23.68 M
|
-$37.38 M
|
-$34.77 M
|
-$20.47 M
|
-$15.56 M
|
-$9.89 M
|
| Net Income Ratio |
-0.89
|
-7.77
|
-7.22
|
-4.11
|
-3.51
|
-6.03
|
-3.85
|
-2.79
|
| EPS |
-13.83 |
-1.59 |
-5.03 |
-19.64 |
-20.8 |
-13.1 |
-17.23 |
-10.21 |
| EPS Diluted |
-13.83 |
-1.59 |
-5.03 |
-19.64 |
-20.8 |
-13.1 |
-17.23 |
-10.21 |
| Weighted Average Shares Out |
$515.57 K
|
$7.77 M
|
$4.71 M
|
$1.90 M
|
$1.67 M
|
$1.56 M
|
$902.69 K
|
$969.12 K
|
| Weighted Average Shares Out Diluted |
$515.57 K
|
$7.77 M
|
$4.71 M
|
$1.90 M
|
$1.67 M
|
$1.56 M
|
$902.69 K
|
$969.12 K
|
| Link |
|
|
|
|
|
|
|
|
